Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary - Thomson StreetEvents

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary - Thomson StreetEvents
Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary
Published Apr 19, 2021
21 pages (11243 words) — Published Apr 19, 2021
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of ALNY.OQ conference call or presentation 19-Apr-21 8:00pm GMT

  
Brief Excerpt:

...A. Highlights: Earlier on 04/19/21, presented full nine-month results from HELIOS-A Phase 3 Study of vutrisiran, an investigational RNAi therapeutic in development for treatment of ATTR amyloidosis. 1. These results were presented at American Academy of Neurology Conference. a. b. Thrilled with these nine-month results in patients with hereditary ATTR amyloidosis with polyneuropathy. 2. Given aforementioned data and considering that vutrisiran is administered as once-quarterly subcutaneously injection, believes that vutrisiran will be a welcome treatment option for patients with hATTR amyloidosis with polyneuropathy, if approved by regulatory authorities. Aforementioned positive phase of HELIOS-A data lay foundation for planned expansion of ATTR franchise into what Co. believes could represent multi-billion dollar opportunity for ALNY over time. a. b. If approved, expects launch of vutrisiran based on current study results will drive significant growth of Co.'s hATTR amyloidosis polyneuropathy...

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Alnylam Pharmaceuticals Inc
Ticker
ALNY.OQ
Time
8:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

Alnylam Pharmaceuticals Inc Annual Shareholders Meeting Transcript – 2021-05-18 – US$ 54.00 – Edited Transcript of ALNY.OQ shareholder or annual meeting 18-May-21 2:30pm GMT

Alnylam Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript – 2021-05-11 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 11-May-21 6:45pm GMT

Alnylam Pharmaceuticals Inc Q1 2021 Earnings Call Summary – 2021-04-29 – US$ 54.00 – Edited Brief of ALNY.OQ earnings conference call or presentation 29-Apr-21 12:30pm GMT

Alnylam Pharmaceuticals Inc Q1 2021 Earnings Call Transcript – 2021-04-29 – US$ 54.00 – Edited Transcript of ALNY.OQ earnings conference call or presentation 29-Apr-21 12:30pm GMT

Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Transcript – 2021-04-19 – US$ 54.00 – Edited Transcript of ALNY.OQ conference call or presentation 19-Apr-21 8:00pm GMT

Alnylam Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript – 2021-04-13 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 13-Apr-21 5:30pm GMT

Alnylam Pharmaceuticals Inc at Stifel CNS Day Transcript – 2021-04-01 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 1-Apr-21 3:00pm GMT

Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference (Virtual) Transcript – 2021-03-10 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 10-Mar-21 6:15pm GMT

Alnylam Pharmaceuticals Inc at H C Wainwright Global Life Sciences Conference (Virtual) Transcript – 2021-03-09 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 9-Mar-21 12:00pm GMT

Alnylam Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript – 2021-03-01 – US$ 54.00 – Edited Transcript of ALNY.OQ presentation 1-Mar-21 7:40pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary" Apr 19, 2021. Alacra Store. May 03, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-Full-9-Month-Results-from-the-HELIOS-A-Phase-3-Study-of-Vutrisiran-Corporate-Call-B14635988>
  
APA:
Thomson StreetEvents. (2021). Alnylam Pharmaceuticals Inc to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran - Corporate Call Summary Apr 19, 2021. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Alnylam-Pharmaceuticals-Inc-to-Discuss-Full-9-Month-Results-from-the-HELIOS-A-Phase-3-Study-of-Vutrisiran-Corporate-Call-B14635988>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.